J

Johnson & Johnson

Makes prescription drugs and medical devices

Manager CSV-Execution Automation Systems

Full-TimeDeadline 10/30/26
No salary listed
Senior, Expert
Bachelor's
Wilson, NC, USA
In PersonFull-time on-site in Wilson; frequent travel over 50% is required during facility design.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A minimum BS degree or equivalent experience in Engineering, Science, or a related field is required.
  • A minimum of 8 years of experience in a manufacturing environment, preferably within the biopharmaceutical or pharmaceutical industry, including at least 2 years in an Execution Systems, Automation, or Information Technology role within a pharmaceutical or Good Manufacturing Practice-regulated manufacturing environment.
  • In-depth knowledge of automation systems, including Emerson DeltaV, OSI PI, Siemens programmable logic controllers, and Information Technology infrastructure and hardware.
  • Experience with Manufacturing Execution Systems, preferably Werum PAS-X, and DeltaV Batch Control.
  • Strong understanding of industrial automation networks and communication protocols.
  • Familiarity with S95 Level 4 systems such as enterprise resource planning, quality systems, data warehouses, and CDL.
  • Expertise in ISA S95 and S88 standards and their application within the Global Supply Chain.
  • Knowledge of current Good Manufacturing Practice regulations related to Computerized System Validation, including 21 CFR Part 11 and EU GMP Annex 11.
  • Proficiency with OSI PI Historian and Werum Manufacturing Execution Systems.
  • Expert-level knowledge of change management and change-control processes for highly integrated recipe and Information Technology systems.
Responsibilities
  • Support automation systems, configure interfaces, ensure compliance with global standards, write and perform validation protocols, participate in compliance inspections, support risk assessments, and support investigations.
  • Apply sound technical engineering concepts to all tasks.
  • Perform validation activities at the site and ensure the approach and execution align with Johnson & Johnson expectations across Information Technology, Execution Systems, and Laboratory Analytical Systems.
  • Work with Information Technology and site organizations to ensure Computerized System Validation packages are consistent with validation plans and standard operating procedures.
  • Provide input on improvements to lifecycle documentation and on standard operating procedure development.
  • Act as a high-level technical resource for policy implementation in partnership with quality organizations to align the approach and acceptance criteria.
  • Support implementation and adoption of the global Computerized System Validation program and remediation, including data-integrity implementation and remediation for systems within the program.
  • Participate in continuous-improvement efforts related to the Computerized System Validation program.
  • Support the Execution Systems organization in achieving site and corporate Computerized System Validation goals.
  • Define Computerized Systems Validation scope and ensure resources, capabilities, and processes are in place.
  • Lead improvement projects related to automation or computerized systems when assigned.
  • Track project cost, quality, and schedule to support effective project execution.
  • Keep programs on target through accurate resourcing and obstacle removal, including communication with senior business stakeholders and supporting partners.
  • Establish working relationships with Quality, Information Technology, Laboratory Systems, Procurement, and other organizations to optimize processes.
  • Serve as the primary Computerized System Validation point of contact at the site.
  • Define, monitor, and report metrics and key performance indicators.
  • Lead the Computerized System Validation team in delivering key projects and lifecycle management.
Desired Qualifications
  • Experience supervising or managing people and resources.
  • Process knowledge for upstream, downstream, and bioprocessing support functions.
  • Proven understanding of GAMP 5 and other recognized industry-standard methodologies.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.

Yahoo Finance
Oct 11th, 2026
J&J reports Q3 results on October 13 as $622.84B giant eyes $2.82 EPS

Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.

Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.